A phase I trial of ZGN 1061 in patients with obesity

Trial Profile

A phase I trial of ZGN 1061 in patients with obesity

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs ZGN 1061 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Zafgen
  • Most Recent Events

    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 12 Sep 2017 Data from this trial presented at the 2017 53rd Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal, according to a Zafgen media release.
    • 10 Jun 2017 Results published in a Zafgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top